Answers are grounded in this paper and cite their sources.
Analysis reveals lower real-world effectiveness of teclistamab in multiple myeloma, suggesting gaps between trial promise and practice.
The real-world effectiveness of the bispecific antibody (BsAb) teclistamab appears to be lower than the efficacy observed in pivotal registration trials. Understanding the drivers of this effectiveness - efficacy gap is essential for guiding the rational selection of patients most likely to benefit, optimizing BsAb therapy in high-risk populations, and ultimately advancing more personalized treatment strategies while supporting sustainable models of care.
No takes yet. Share an insight, caveat, or question.
Zweegman et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: